바이오인

출처 : ERNST   &   YOUNG

What Europe has to offer biotechnology companies

 Unraveling the tax, financial and regulatory framework

Executive summary

National governments have done much to encourage innovation, often through a web of tax incentives for research. Yet, by and large, they have done too little to ensure that these ideas are translated into new businesses, new products, additional jobs and so, in time, a faster rate of economic growth.

What Europe has to offer biotechnology companies: Unraveling the tax, financial and regulatory framework is a joint report by Ernst & Young and EuropaBio. In it, we examine what European countries have to offer investors, entrepreneurs and researchers alike. We look at everything from what to take into account when determining the best location for research and development to how best exploit intellectual property (IP) within Europe’s various jurisdictions.

At a time when big biotechnology companies are looking for inspiration, governments need to encourage small and medium-sized enterprises (SMEs) to take steps which may help them one day to become large firms in their own right. There is more to creating a successful industry, says the report, than putting in place the right standard of regulation. What is needed is a climate of innovation, coupled with the bricks and mortar with which to build industries around it.

.........(계속)

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.